6.7551
price up icon2.50%   0.1651
 
loading
Schlusskurs vom Vortag:
$6.59
Offen:
$6.66
24-Stunden-Volumen:
1.42M
Relative Volume:
1.00
Marktkapitalisierung:
$706.79M
Einnahmen:
$73.48M
Nettoeinkommen (Verlust:
$-108.30M
KGV:
-3.0023
EPS:
-2.25
Netto-Cashflow:
$-67.17M
1W Leistung:
-13.84%
1M Leistung:
-17.72%
6M Leistung:
+15.47%
1J Leistung:
+89.22%
1-Tages-Spanne:
Value
$6.6505
$7.105
1-Wochen-Bereich:
Value
$6.56
$8.4156
52-Wochen-Spanne:
Value
$2.8262
$11.50

Personalis Inc Stock (PSNL) Company Profile

Name
Firmenname
Personalis Inc
Name
Telefon
650-752-1300
Name
Adresse
6600 DUMBARTON CIRCLE, FREMONT, CA
Name
Mitarbeiter
260
Name
Twitter
@PersonalisInc
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
PSNL's Discussions on Twitter

Compare PSNL vs TMO, DHR, IDXX, A, WAT

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Diagnostics & Research icon
PSNL
Personalis Inc
6.755 689.52M 73.48M -108.30M -67.17M -2.25
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
467.11 176.79B 44.56B 6.72B 6.29B 17.74
Diagnostics & Research icon
DHR
Danaher Corp
186.91 131.71B 24.57B 3.60B 5.26B 5.051
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
573.51 45.48B 4.30B 1.06B 1.04B 13.08
Diagnostics & Research icon
A
Agilent Technologies Inc
111.60 31.55B 7.07B 1.29B 993.00M 4.5355
Diagnostics & Research icon
WAT
Waters Corp
286.32 27.79B 3.17B 642.63M 516.49M 10.77

Personalis Inc Stock (PSNL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-12-02 Fortgesetzt Morgan Stanley Equal-Weight
2025-05-15 Eingeleitet Guggenheim Buy
2025-03-17 Eingeleitet Craig Hallum Buy
2023-02-06 Hochstufung Needham Hold → Buy
2022-01-07 Hochstufung BofA Securities Neutral → Buy
2021-11-05 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-11-03 Herabstufung Needham Buy → Hold
2021-10-15 Fortgesetzt Cowen Outperform
2021-09-20 Bestätigt Needham Buy
2021-05-06 Hochstufung Oppenheimer Perform → Outperform
2021-01-28 Eingeleitet Truist Buy
2021-01-04 Herabstufung BofA Securities Buy → Neutral
2020-11-12 Bestätigt Needham Buy
2020-11-06 Herabstufung Oppenheimer Outperform → Perform
2020-10-19 Eingeleitet Citigroup Buy
2020-10-08 Eingeleitet BTIG Research Buy
2020-08-27 Eingeleitet H.C. Wainwright Buy
2020-08-18 Eingeleitet Needham Buy
2019-09-26 Hochstufung BofA/Merrill Neutral → Buy
2019-07-15 Eingeleitet BofA/Merrill Neutral
2019-07-15 Eingeleitet Cowen Outperform
2019-07-15 Eingeleitet Morgan Stanley Overweight
2019-07-15 Eingeleitet Oppenheimer Outperform
Alle ansehen

Personalis Inc Aktie (PSNL) Neueste Nachrichten

pulisher
Mar 12, 2026

Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal - BioSpace

Mar 12, 2026
pulisher
Mar 12, 2026

Personalis (PSNL) Publishes Promising Study on Cancer Detection Method - GuruFocus

Mar 12, 2026
pulisher
Mar 12, 2026

Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal® - Business Wire

Mar 12, 2026
pulisher
Mar 11, 2026

Personalis, Inc. (NASDAQ:PSNL) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Mar 11, 2026
pulisher
Mar 10, 2026

Growth Report: Is Personalis Inc showing insider buyingEarnings Growth Report & Consistent Profit Trade Alerts - baoquankhu1.vn

Mar 10, 2026
pulisher
Mar 08, 2026

Personalis (NASDAQ:PSNL) Rating Increased to Hold at Wall Street Zen - MarketBeat

Mar 08, 2026
pulisher
Mar 06, 2026

Momentum Shift: Is Personalis Inc benefiting from interest rate changesJuly 2025 Earnings & Short-Term Trading Opportunity Alerts - baoquankhu1.vn

Mar 06, 2026
pulisher
Mar 06, 2026

Is Personalis Inc. stock attractive after correctionTrade Risk Summary & Weekly High Momentum Picks - Naître et grandir

Mar 06, 2026
pulisher
Mar 06, 2026

Personalis Stock Pre-Market (-5.3%): FY26 Guidance Overshadows Q4 EPS Beat - Trefis

Mar 06, 2026
pulisher
Mar 05, 2026

Morgan Stanley Has Lowered Expectations for Personalis (NASDAQ:PSNL) Stock Price - MarketBeat

Mar 05, 2026
pulisher
Mar 05, 2026

PSNL: Morgan Stanley Maintains Equal-Weight, Lowers Price Target - GuruFocus

Mar 05, 2026
pulisher
Mar 05, 2026

Personalis, Inc. $PSNL Stake Boosted by ARK Investment Management LLC - MarketBeat

Mar 05, 2026
pulisher
Mar 04, 2026

Personalis, Inc. (NASDAQ:PSNL) Short Interest Up 21.2% in February - MarketBeat

Mar 04, 2026
pulisher
Mar 02, 2026

Personalis (NASDAQ:PSNL) Shares Gap DownTime to Sell? - MarketBeat

Mar 02, 2026
pulisher
Mar 01, 2026

Will Personalis Inc. outperform small cap indexesBear Alert & Free Verified High Yield Trade Plans - mfd.ru

Mar 01, 2026
pulisher
Feb 28, 2026

Breaking Down Personalis: 5 Analysts Share Their Views - Sahm

Feb 28, 2026
pulisher
Feb 28, 2026

Personalis, Inc. (NASDAQ:PSNL) Q4 2025 Earnings Call Transcript - Insider Monkey

Feb 28, 2026
pulisher
Feb 28, 2026

Personalis (NASDAQ:PSNL) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat

Feb 28, 2026
pulisher
Feb 27, 2026

Personalis 2025 Financial Results: Revenue, Loss, and 2026 ForecastNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform

Feb 27, 2026
pulisher
Feb 27, 2026

Personalis, Inc. (PSNL) Stock Analysis: Exploring a Promising 24.98% Upside with Innovative Cancer Genomics - DirectorsTalk Interviews

Feb 27, 2026
pulisher
Feb 27, 2026

Personalis (NASDAQ:PSNL) Price Target Raised to $12.00 at Needham & Company LLC - MarketBeat

Feb 27, 2026
pulisher
Feb 27, 2026

Personalis, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Feb 27, 2026
pulisher
Feb 27, 2026

Needham raises Personalis stock price target on reimbursement wins By Investing.com - Investing.com Nigeria

Feb 27, 2026
pulisher
Feb 27, 2026

Needham raises Personalis stock price target on reimbursement wins - Investing.com Australia

Feb 27, 2026
pulisher
Feb 27, 2026

PSNL Stock Sees Price Target Increase by Needham | PSNL Stock Ne - GuruFocus

Feb 27, 2026
pulisher
Feb 27, 2026

Personalis stock price target reaffirmed at $13 by BTIG on MRD growth - Investing.com South Africa

Feb 27, 2026
pulisher
Feb 27, 2026

Personalis Q4 Earnings Call Highlights - MarketBeat

Feb 27, 2026
pulisher
Feb 27, 2026

Personalis Inc (PSNL) Q4 2025 Earnings Call Highlights: Robust C - GuruFocus

Feb 27, 2026
pulisher
Feb 27, 2026

Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights - BioSpace

Feb 27, 2026
pulisher
Feb 27, 2026

Personalis Inc (PSNL) Q4 2025 Earnings Call Highlights: Robust Clinical Growth Amidst Revenue ... By GuruFocus - Investing.com Canada

Feb 27, 2026
pulisher
Feb 26, 2026

Personalis (NASDAQ:PSNL) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat

Feb 26, 2026
pulisher
Feb 26, 2026

Personalis: Q4 Earnings Snapshot - theheraldreview.com

Feb 26, 2026
pulisher
Feb 26, 2026

Personalis (PSNL) Q4 2025 Earnings Call Transcript - AOL.com

Feb 26, 2026
pulisher
Feb 26, 2026

Earnings call transcript: Personalis Q4 2025 sees EPS beat but revenue miss - Investing.com

Feb 26, 2026
pulisher
Feb 26, 2026

Personalis (PSNL) Offers FY26 Revenue Forecast Below Expectations - GuruFocus

Feb 26, 2026
pulisher
Feb 26, 2026

Personalis (PSNL) Reports Q4 Loss, Misses Revenue Estimates - Nasdaq

Feb 26, 2026
pulisher
Feb 26, 2026

PSNL Achieves Strong Q4 Revenue and Prepares for Significant Gro - GuruFocus

Feb 26, 2026
pulisher
Feb 26, 2026

Personalis Inc reports results for the quarter ended September 30Earnings Summary - TradingView

Feb 26, 2026
pulisher
Feb 26, 2026

Progyny Inc. (PGNY) Stock Falls on Q4 2025 Earnings - Quiver Quantitative

Feb 26, 2026
pulisher
Feb 26, 2026

[10-K] Personalis, Inc. Files Annual Report | PSNL SEC FilingForm 10-K - Stock Titan

Feb 26, 2026
pulisher
Feb 26, 2026

Personalis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Feb 26, 2026
pulisher
Feb 26, 2026

Earnings Breakdown: Personalis Q4 - Benzinga

Feb 26, 2026
pulisher
Feb 26, 2026

Personalis (NASDAQ: PSNL) details 2025 results and 2026 growth plan - Stock Titan

Feb 26, 2026
pulisher
Feb 26, 2026

Personalis, Inc. Provides Earnings Guidance for the Full Year of 2026 - marketscreener.com

Feb 26, 2026
pulisher
Feb 26, 2026

Personalis earnings beat by $0.04, revenue fell short of estimates - Investing.com Canada

Feb 26, 2026
pulisher
Feb 26, 2026

Personalis: Overview of Fourth Quarter Financial Results - Bitget

Feb 26, 2026
pulisher
Feb 25, 2026

[Form 4] Personalis, Inc. Insider Trading Activity - Stock Titan

Feb 25, 2026
pulisher
Feb 25, 2026

Personalis (PSNL) CEO gains 33,333 performance-based stock options - Stock Titan

Feb 25, 2026
pulisher
Feb 20, 2026

How Personalis Inc. stock performs in weak economyJuly 2025 Macro Moves & Entry Point Confirmation Alerts - mfd.ru

Feb 20, 2026
pulisher
Feb 20, 2026

Personalis (NASDAQ:PSNL) Shares Down 4.8%Should You Sell? - MarketBeat

Feb 20, 2026
pulisher
Feb 19, 2026

Aberdeen Group plc Increases Stock Position in Personalis, Inc. $PSNL - MarketBeat

Feb 19, 2026

Finanzdaten der Personalis Inc-Aktie (PSNL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Personalis Inc-Aktie (PSNL) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Tempus AI, Inc.
10% Owner
Nov 25 '25
Buy
10.62
23,600
250,665
12,918,346
Tempus AI, Inc.
10% Owner
Dec 22 '25
Buy
8.93
28,000
250,040
13,039,067
Tempus AI, Inc.
10% Owner
Nov 21 '25
Buy
9.40
26,499
249,190
12,869,521
Tempus AI, Inc.
10% Owner
Nov 24 '25
Buy
9.87
25,225
248,971
12,894,746
Tempus AI, Inc.
10% Owner
Nov 19 '25
Buy
8.12
30,645
248,837
12,814,195
Tempus AI, Inc.
10% Owner
Nov 20 '25
Buy
8.63
28,827
248,777
12,843,022
Tempus AI, Inc.
10% Owner
Dec 17 '25
Buy
7.86
31,650
248,769
12,949,996
Tempus AI, Inc.
10% Owner
Dec 19 '25
Buy
8.39
29,641
248,688
13,011,067
Tempus AI, Inc.
10% Owner
Dec 18 '25
Buy
7.91
31,430
248,611
12,981,426
Tachibana Aaron
CFO AND COO
Jan 22 '26
Option Exercise
9.16
1,201
11,001
165,659
diagnostics_research LH
$264.90
price up icon 0.76%
diagnostics_research DGX
$199.87
price down icon 0.53%
diagnostics_research MTD
$1,179.61
price up icon 0.93%
$188.84
price down icon 0.09%
diagnostics_research IQV
$165.22
price up icon 1.56%
diagnostics_research WAT
$286.87
price up icon 1.30%
Kapitalisierung:     |  Volumen (24h):